Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. The Tenaya Therapeutics news feed highlights company announcements, clinical data updates and financial disclosures related to its gene therapy and small molecule programs for genetic cardiomyopathies and heart failure.
News about Tenaya frequently centers on TN-201, its AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Company press releases provide interim safety, biopsy and early efficacy results from the MyPEAK-1 and RIDGE-1 Phase 1b/2 clinical trials, including observations on protein expression, arrhythmia measures and biomarkers.
Investors and followers of TNYA can also find updates on regulatory interactions, such as FDA designations and clinical hold communications, as well as information on Tenaya’s capital-raising activities through public offerings described in SEC filings and related press releases. Additional news items cover participation in scientific and investor conferences, late-breaking presentations at major cardiology and gene therapy meetings, and publications that describe Tenaya’s research platforms and preclinical findings.
This page aggregates these disclosures so readers can review Tenaya Therapeutics’ latest reported milestones, from clinical trial progress for TN-201 and TN-401 to developments in its broader pipeline, including the TN-301 small molecule HDAC6 inhibitor and early-stage preclinical programs. For those tracking TNYA, the news stream offers a consolidated view of how the company reports advancing its mission to address genetic drivers of heart disease.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $15.00 each, set to trade on the Nasdaq from July 30, 2021. The IPO is expected to generate gross proceeds of $180 million, with an option for underwriters to purchase an additional 1.8 million shares. The offering closes on August 3, 2021, pending usual conditions, with Morgan Stanley, Cowen, and Piper Sandler as joint book-running managers. Tenaya aims to develop therapies for heart disease, leveraging expertise from top scientific institutions.